Clozapine is the only licensed pharmacotherapy for treatment-resistant schizophrenia.
However, response to clozapine is variable. Understanding the demographic and clinical …

Objectives Clozapine (CLZ) is prescribed to (relatively) treatment-resistant patients with
schizophrenia spectrum disorders. Currently, it is unknown what factors predict response to …

Background Clozapine has been serving as the gold standard medication for patients with
treatment-resistant schizophrenia who failed to respond to other antipsychotics. However …

Objective Early treatment of schizophrenia improves outcomes. Clozapine appears to have
unique benefit when other antipsychotic medication has failed. This systematic review and …

We aimed to identify factors associated with greater clozapine response to guide targeted
clozapine use. The study was based on data from the Danish Psychiatric Central Research …

Background Earlier commencement of clozapine has been related to a better response in
treatment-resistant schizophrenia. Objectives To identify variables that predict clozapine use …

Background This study investigates whether early clozapine use is associated with
improved responses in different clinical domains, including positive and negative symptoms …

Background Although clozapine is the most effective drug for treatment-resistant
schizophrenia, its use remains restricted in clinical practice in India. The delay in initiating …

BACKGROUND: Several lines of evidence suggest that clozapine is more effective than both
first-and second-generation antipsychotic drugs in treatment-resistant schizophrenia (TRS) …

Slow titration of clozapine is recommended given the risk of serious adverse effects.
However, the utility and safety of slower-than-recommended titration of clozapine remain …